Minesh Kothari

Trial supported Orphalan’s successful application to the United States Food and Drug Administration (FDA) for approval of Cuvrior™ (trientine tetrahydrochloride) for Wilson’s disease Paris, France 30 September, 2022 - Orphalan…

World’s first global Wilson’s Registry will provide an international platform for sharing real-world information about Wilson’s disease Registry expected to include 500 individuals affected by this rare disease Paris, France…

Conversation between Omar Kamlin, Senior Medical Director at Orphalan SA and Prof Pramod Mistry, MBBS, PhD, MA, MD, Director of Yale Lysosomal Disease Center and Gaucher Disease Treatment Center at…

Paris, France 1 February 2022 – Orphalan SA, a Company that identifies, develops, and delivers therapies worldwide for orphan diseases, today announces two new appointments to the management team. Tim…